These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression? Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736 [TBL] [Abstract][Full Text] [Related]
34. [Clinical and histological features of non-alcoholic fatty liver disease]. Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638 [TBL] [Abstract][Full Text] [Related]
35. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Vernon G; Baranova A; Younossi ZM Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852 [TBL] [Abstract][Full Text] [Related]
36. Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease. Chandok N; Minuk G; Wengiel M; Uhanova J J Gastrointestin Liver Dis; 2012 Mar; 21(1):53-8. PubMed ID: 22457860 [TBL] [Abstract][Full Text] [Related]
37. From the metabolic syndrome to NAFLD or vice versa? Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596 [TBL] [Abstract][Full Text] [Related]
38. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Moore JB Proc Nutr Soc; 2010 May; 69(2):211-20. PubMed ID: 20158939 [TBL] [Abstract][Full Text] [Related]
40. Biomarkers for early detection of non-alcoholic steatohepatitis: implications for drug development and clinical trials. Yilmaz Y Curr Drug Targets; 2013 Oct; 14(11):1357-66. PubMed ID: 24020975 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]